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The effect of dose or dose interval on the pharmacodynamics of simulated high-dose intravenous
ciprofloxacin therapy on infection due to Pseudomonas aeruginosa and Staphylococcus aureus was studied in an
in vitro hollow-fiber model of infection. Simulated doses of 1,200 mg of ciprofloxacin per day as either 400 mg
every 8 h or 600 mg every 12 h against P. aeruginosa resulted in selection of ciprofloxacin-resistant bacteria.
The results with one test strain that was isolated from a patient prior to administration of intravenous
ciprofloxacin demonstrated selection of a gyrA mutant in the model, as had occurred in vivo. A single 1,200-mg
dose every 24 h did not select for bacterial resistance; however, breakthrough regrowth of ciprofloxacin-
susceptible bacteria occurred. Dosages of 400 or 600 mg of ciprofloxacin every 12 h effectively reduced bacterial
counts of one strain each of methicillin-susceptible or -resistant S. aureus, with no bacterial resistance detected
at the end of experiment; in contrast, 200 mg every 12 h resulted in bacterial regrowth due to the selection of
drug-resistant bacteria. These data show the need for high-dose intravenous ciprofloxacin, particularly with
regimens producing high peak levels, for treatment of infections where selection for bacterial resistance is a
clinical problem.
Despite significant clinical experience with ciprofloxacin
and other fluoroquinolones, the optimal dose and schedule
for treatment remain unknown. Elucidation of the pharma-
codynamic variables most predictive of a favorable response
leads to the design of optimal dosing regimens. This may be
particularly important for infections due to organisms such
as Pseudomonas aeruginosa and Staphylococcus aureus, for
which the MICs of most fluoroquinolones are at or slightly
below the breakpoint for susceptibility and for which selec-
tion for bacterial resistance has been associated with failure
to respond clinically (9, 12, 16-18, 21).
This study evaluated the effects of various doses and
dosing intervals of ciprofloxacin against P. aeruginosa and
S. aureus in an in vitro model of infection. Several pharma-
cokinetic and pharmacodynamic variables were examined to
ascertain those associated with bacterial eradication and
suppression of resistant bacterial subpopulations, including
strains whose mechanism of resistance had been previously
characterized by using specific probes.
MATERIALS AND METHODS
Bacteria. All bacterial test isolates were provided by
N.J.R. Two strains each of P. aeruginosa and S. aureus
were studied. For all strains an inoculum of -5 x 105
CFU/ml had mode MICs of ciprofloxacin of 1 mg/liter in
cation-supplemented Mueller-Hinton broth (MHB-S), as as-
sessed by the tube broth macrodilution method (15). P.
aeruginosa MP001 is a pretherapy clinical isolate obtained
from a patient with mediastinitis and empyema; two cipro-
floxacin-resistant gyrA (c5rA) mutants (MP002 and MP003)
* Corresponding author.
of this strain with ciprofloxacin MICs of 8 and 16 mg/liter,
respectively, were isolated from the patient after intrave-
nous ciprofloxacin therapy (12). P. aernginosa PAO2, a
well-characterized laboratory strain, was also studied in the
model. Selection of ciprofloxacin-resistant mutants on agar
containing 2 times the MIC of drug occurs at a frequency of
-10' (20). These isolates had both the cfx4 and cfxB
chromosomal mutations, alone or combined, as well as
changes in outer membrane proteins (20).
Two strains of S. aureus were tested. Strain MP1200 is a
methicillin-resistant strain of S. aureus, and MP1201 is a
methicillin-susceptible strain of S. aureus.
In vitro model. Hollow-fiber bioreactor chambers (Cell-
Pharm Mini-Bioreactor System; CD Medical, Inc., Miami
Lakes, Fla.) were connected in series to a central compart-
ment in an incubator as previously described (2). The
volume of each peripheral chamber was 15 ml. The central
compartment diluent was MHB-S; peripheral compartments
contained 10% heat-inactivated human serum plus 90%
MHB-S. Following a dose of ciprofloxacin, the drug was
eliminated by pumping drug-free MHB-S into the central
compartment at a rate adjusted to simulate the human
pharmacokinetics of the drug.
The bacteria used for all experiments were prepared from
inocula previously grown, aliquoted, and frozen in a mixture
of brain heart infusion broth and fetal calf serum (60:40). On
the day of an experiment, the frozen inoculum was thawed,
diluted with fresh MHB-S, and incubated for 1 to 2 h to bring
organisms into the log-linear growth phase. The bacteria
were then injected into the peripheral compartments of the
model and incubated for 2 h to reach an inoculum of about 2
x 106 CFU/ml.
Samples (1 to 1.5 ml) were collected from the central and
peripheral compartments over 30 h and assayed for drug
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FIG. 1. Ciprofloxacin concentrations measured in the central compartment for the three dosage regimens against both strains of P.
aeruginosa (top) and S. aureus (bottom). TID, every 8 h; BID, every 12 h; QD, every 24 h.
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TABLE 1. Ciprofloxacin pharmacokinetic parameters in the in vitro model relative to the initial MIC, based on measured drug
concentrations for different dosage regimens
Organism and Peak/MICb Peak - MIC' Time > MICI (h) AUC > MICE (mg* h/liter)
regimen' (mg/liter) 0-8 h 0-24 h 0-8 h 0-24 h
P. aeruginosa
400 mg TID 4.2 3.2 7.5 23 7.9 23
600 mg BID 6 5 8 20 17 38
1,200 mg QD 11 10 8 13 40 43
S. aureus
200 mg BID 2.2 1.2 5 10 2.3 4.7
400 mg BID 5.9 4.9 8 18 18.3 35.4
600 mg BID 6.8 5.8 8 24 28.6 62.8
a TID, every 8 h; BID, every 12 h; QD, every 24 h.
b Ratio of peak drug concentration to MIC.
Difference between peak drug concentration and MIC.
d Time that ciprofloxacin concentration exceeded the MIC.
e Area under the ciprofloxacin concentration-time curve that exceeded the MIC.
(central and peripheral chambers) and bacterial (peripheral
chambers) concentrations. Ciprofloxacin concentrations in
samples from experiments with P. aeruginosa were mea-
sured by high-pressure liquid chromatography (HPLC) (10).
Bioassay by a previously described method was used to
measure drug concentrations in the central compartment in
experiments with S. aureus (6). The between-day variability
and accuracy of the HPLC and bioassay methods were
<10%.
Bacteria were quantified by placing samples serially di-
luted in cold saline on drug-free Mueller-Hinton agar (MHA)
plates, incubating at 37°C, and counting colonies. Samples
with very low numbers of bacteria were placed in 10 ml of
cold saline and then filtered with a 0.45-p,m filter (Millipore
Corporation, Bedford, Mass.). The filter was then placed
directly on drug-free MHA and incubated. The limit of
detection by this method was 10 CFU/ml.
Dosage regimens and pharmacokinetics. Initial experiments
were conducted with a fixed daily exposure of 1,200 mg of
ciprofloxacin given as 600 mg every 12 h. Subsequent
reduction or fractionation of the total daily dose was based
on results with this regimen; if divided doses of 600 mg every
12 h effectively reduced bacterial CFU per milliliter with no
regrowth due to selection of resistant bacteria, the daily
exposure would be lowered to 400 mg every 12 h and then to
200 mg every 12 h until a dose resulting in no net bacterial
killing by 24 h was reached. If bacterial regrowth and/or
resistance occurred following the initial regimen of 600 mg
every 12 h, the total daily dose was fractionated as either 400
mg every 8 h or 1,200 mg every 24 h. Doses were given as
60-min constant-rate infusions. The elimination half-life of
ciprofloxacin in the model was adjusted to 3.5 h (7).
Pharmacokinetic and pharmacodynamic parameters for
each regimen were calculated by using measured ciproflox-
acin concentrations in the central compartment and pretreat-
ment MICs. Previous studies with these bioreactor units
showed rapid equilibration of drug between the compart-
ments. This allows one to focus on exposure profiles in the
analogous "intravascular" compartment. The parameters
calculated included the relation of the peak drug concentra-
tion to the MIC as either a ratio or a difference, the time that
the ciprofloxacin concentration exceeded the MIC, and the
area under the ciprofloxacin concentration-time curve that
exceeded the MIC (5).
Drug resistance. Samples taken prior to drug exposure
(time zero) and at 24 h were placed on MHA plates contain-
ing no drug or 0.5, 1, or 4 mg of ciprofloxacin per liter to
quantify ciprofloxacin-resistant bacterial subpopulations.
The MICs for post-treatment isolates recovered on drug-free
plates also were determined by broth macrodilution.
Eight isolates of P. aeruginosa recovered from the model
on ciprofloxacin-containing or drug-free plates prior to or 24
h after the first drug dose were probed for a gyrA mutation
by using a broad-host-range gyrase A gene probe (19). This
probe, pNJR3-2, consists of an Escherichia coli gyrase A
gene cloned into the cosmid vector pLA2917. Previous
studies of matings of NJR3-2 into resistant mutants of MP001
(selected during therapy) and PAO2 showed that it is capable
of restoring pure gyrA (i.e., cfr) mutants to wild-type
susceptibility. The probe has no effect on fully susceptible or
cfrB mutants and only partially restores susceptibility of
cfxA cfiB double mutants of PAO2 (19).
Isolates recovered on drug-containing plates were passed
three times on plates containing the same concentration of
ciprofloxacin and once onto drug-free MHA and then trans-
ferred onto a Trypticase soy agar slant for transport and
storage for probe studies. Bacterial isolates recovered on
drug-free plates were passed one or two times on drug-free
MHA and then transferred onto a Trypticase soy agar slant.
In addition, several isolates were frozen in glycerol for
longer-term storage prior to probe studies. Bacterial isolates
recovered from the model were incubated with E. coli S17-1
containing the vector plasmid pLA2917 (negative control) or
pNJR3-2 overnight in broth, and passed onto Pseudomonas
isolation medium as previously described (19). A known
cfxA mutant of PAO2 was used as a positive control. An
isolate demonstrating an increase in ciprofloxacin suscepti-
bility following exposure to the probe relative to that of the
pretreatment isolate was judged to have a pure gyrA muta-
tion.
RESULTS
Pharmacokinetics. Figure 1 depicts ciprofloxacin concen-
trations in the central compartment of the model for the
three dosage regimens tested against each strain. Drug
concentrations in samples collected simultaneously from the
central and all peripheral chambers of the model were with
10 to 15% of each other; thus, concentrations in the central
compartment were used in pharmacokinetic-pharmacody-
namic calculations. Pharmacokinetic parameters related to
the MIC are shown in Table 1. As would be expected, the
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FIG. 2. Pharmacodynamics of ciprofloxacin for three different dosage regimens against P. aeruginosa MP001 (top) and P. aeruginosa
PA02 (bottom). Datum points are geometric means plus standard deviations for three replicate chambers. For abbreviations, see the legend
to Fig. 1.
ratio of and difference between the peak concentration and
MIC increased, the area under the curve that exceeded the
MIC increased, and the time that the concentration ex-
ceeded the MIC decreased as dose size (and interval) in-
creased. With the regimen of 400 mg every 8 h, ciprofloxacin
concentrations essentially always exceeded the initial MIC
(1 mg/liter) for both strains. With the regimens of 600 mg
every 12 h and 1,200 mg every 24 h, drug concentrations
exceeded the initial MIC for only 80 and 54% of the dosing
interval, respectively.
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FIG. 3. Recovery of P. aeruginosa MP001 (top) and P. aerugi-
nosa PA02 (bottom) on MHA containing no drug or 0.5, 1.0, or 4.0
mg of ciprofioxacin per liter. Organisms were recovered at 24 h
following exposure to three different ciprofloxacin dosage regimens.
The broth MICs for organisms recovered on drug-free plates are also
shown. For abbreviations, see the legend to Fig. 1.
Experiments with S. aureus utilized a fixed 12-h dosing
interval; thus, changes in parameters were proportional to
dose size (Table 1). With the 200-mg dose, the concentration
exceeded the MIC for only 5 h of the 12-h dosing interval,
whereas the 400- and 600-mg doses produced concentrations
which exceeded the MIC for cumulative periods of 18 and 24
h, respectively, of a 24-h interval. The area under the curve
that exceeded the MIC was severalfold higher for the 400-
and 600-mg doses relative to the 200-mg dose.
Pharmacodynamics and bacterial resistance. (i) P. aerugi-
nosa. The first dose with all regimens resulted in a marked
bactericidal effect (about a 5-log reduction in CFU per
milliliter) over the first 4 h in both strains (Fig. 2). With strain
MP001, regrowth occurred before the second dose with all
regimens; bacterial counts returned to the level of the initial
inoculum by 24 h despite subsequent doses with the regi-
mens of 400 mg every 8 h and 600 mg every 12 h (Fig. 2, top).
In contrast, the subsequent 1,200-mg dose given at 24 h
resulted again in marked killing of this strain.
A similar but less pronounced pattern was observed with
strain PAO2; initial killing with the regimens of 400 mg every
8 h and 600 mg every 12 h was followed by bacteriostasis and
slight regrowth with subsequent doses (Fig. 2, bottom).
However, the second 1,200-mg dose with the regimen of
1,200 mg every 24 h exerted a marked bactericidal effect
against this strain; this was also observed in strain MP001.
The susceptibility of bacteria recovered at 24 h following
exposure to 400 mg every 8 h or 600 mg every 12 h
demonstrated that the majority of organisms were resistant
to 1 mg of ciprofloxacin per liter (Fig. 3); for strain MP001,
a small proportion was resistant to 4 mg/liter. The ciproflox-
acin MIC (in MHB-S) for bacteria recovered on the drug-free
plate was 4 mg/liter. In contrast to the every-8- or -12-h
regimens, subpopulation analysis with the regimen of 1,200
mg every 24 h revealed that either only a small proportion of
the inoculum was resistant to 1 mg of ciprofloxacin per liter
(strain MP001; Fig. 3, top) or all organisms remained sus-
ceptible to 1 mg/liter (strain PAO2; Fig. 3, bottom). The MIC
in MHB-S for bacteria recovered on drug-free medium
following the single large dose did not change for strain
MP001 and increased only slightly (from 1 to 2 mg/liter) for
strain PAO2.
DNA gene probe analysis of isolates from both strains of
P. aeruginosa at 24 h showed selection of puregyrA mutants
only in strain MP001. These mutants were recovered on the
drug-free plate following the regimen of 600 mg every 12 h.
In the other case they were detected in one of the three
distinct colony morphology types tested from a plate con-
taining 0.5 mg of ciprofloxacin per liter following the regimen
of 1,200 mg every 24 h. No pure gyrA mutants were detected
with the regimen of 400 mg every 8 h against this strain or
with any regimen with strain PAO2, indicating that changes
in susceptibility were of the cfxB type or perhaps were
double mutations.
(ii) S. aureus. Dosing of 400 or 600 mg of ciprofloxacin
every 12 h resulted in rapid and complete killing of both
strains of S. aureus, with no selection for ciprofloxacin-
resistant bacteria during the experiment (Fig. 4, top). How-
ever, with the regimen of 200 mg every 12 h, an initial 4- to
5-log kill was followed by bacterial regrowth within 10 h after
the first dose for both strains (Fig. 4, bottom). The second
200-mg dose at 12 h produced some bacterial killing but was
followed by sustained bacterial regrowth; the final dose at 24
h had no significant effect on bacterial counts.
Analysis of isolates of both strains at 24 h following the
regimen of 200 mg every 12 h revealed bacterial subpopula-
tions resistant to 1 mg of ciprofloxacin per liter (Fig. 5); a
small proportion of the inoculum of the methicillin-resistant
strain was also resistant to 4 mg of ciprofloxacin per liter. A
fourfold rise in MIC in MHB-S (from 1 to 4 mg/liter) for
bacteria recovered on drug-free plates was observed for both
strains. The basis of increased resistance in these strains was
not investigated.
DISCUSSION
Although the fluoroquinolones have been established as
effective agents in the treatment of a number of infections,
bacterial resistance has limited their usefulness in serious
infections due to certain organisms. Among gram-negative
bacteria, P. aeruginosa has often been associated with
changes in susceptibility to ciprofloxacin following therapy
1760 MARCHBANKS ET AL.
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FIG. 4. Pharmacodynamics of ciprofloxacin following 400 or 600 mg every 12 h (top) and 200 mg every 12 h (bottom) against a
methiciHin-susceptible (MSSA) and a methicillin-resistant (MRSA) strain of S. aureus. Datum points are geometric means plus standard
deviations for three replicate chambers.
(12, 14, 16, 21, 22); this has been a particular problem with
intravenous dosage regimens of 200 to 300 mg twice daily (6,
17). The mechanism of resistance in gram-negative bacilli
seems to be of two types. Alterations in DNA gyrase (gyrA
mutation) occur at a frequency of 10-7 and are associated
with a 4- to 16-fold increase in the MIC compared with that
for wild-type strains (22). Bacteria may also develop changes
in outer membrane permeability to ciprofloxacin, thus limit-
ing access of the drug to the cytoplasmic target site (3).
Resistance of methicillin-susceptible and -resistant strains of
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FIG. 5. Recovery of S. aureus on agar plates containing no drug
or 0.5, 1.0, or 4.0 mg of ciprofloxacin per liter from two replicate
chambers. Organisms tested were those recovered at 24 h following
exposure to 200 mg of ciprofloxacin every 12 h. The broth MICs for
organisms recovered on drug-free plates are also shown. For abbre-
viations, see the legend to Fig. 4.
S. aureus to ciprofloxacin and other fluoroquinolones is an
increasing problem which has limited the use of these agents
in the treatment of serious infections due to these organisms
(13, 20).
In view of the clinical problem of bacterial resistance with
fluoroquinolone therapy of infection due to these species, we
studied the role of pharmacokinetics in the selection of
resistance. The dosage regimens tested higher simulated
levels of exposure of ciprofloxacin than have been studied
systematically to date in humans. Our studies included
experiments with isolates of P. aeruginosa whose genotypic
and phenotypic bases for resistance following exposure to
ciprofloxacin were previously well characterized. One of the
strains tested in our model was a pretherapy isolate recov-
ered from a patient whose failure to respond to intravenous
ciprofloxacin therapy was proven to be due to selection of a
drug resistant gyrA mutant of the same strain (12, 16).
Studies using the model with the pretherapy isolate of this
strain (M0001) showed that a high-dose regimen of 1,200 mg
of ciprofloxacin per day given as either 400 mg every 8 h or
600 mg every 12 h resulted in the selection of ciprofloxacin-
resistant bacteria with a gyrA mutation, as had been de-
scribed previously for this organism (12). While the scope of
comparisons is indeed limited, these data suggest that the
endpoints observed in the in vitro model for a dosage
regimen may forecast the response to human infection with
a similarly large bacterial inoculum (5).
The killing of P. aeruginosa by ciprofloxacin was initially
rapid and then slow prior to regrowth due to bacterial
resistance (2). This biphasic killing pattern has been noted
previously in experiments using static concentrations of drug
(4, 23). Although adaptive resistance has not been described
for fluroquinolones, Wolfson et al. have described selection
of partially tolerant mutants of E. coli in vitro following
exposure to norfloxacin (23).
Although bacterial regrowth was observed within 6 to 8 h
with all of the dosage regimens for P. aeruginosa, the
regrowth that occurred following exposure to a single
1,200-mg dose was due not to ciprofloxacin-resistant bacte-
ria but to breakthrough growth of susceptible bacteria. This
was evident by the marked bactericidal effect of a subse-
quent dose given at 24 h. Therefore, for these strains of P.
aeruginosa, exposure to 1,200 mg of ciprofloxacin per day
given as any regimen in the model was incapable of prevent-
ing the selection of drug-resistant bacteria or causing a net
reduction of bacterial counts over a 24-h period. Bacterial
regrowth occurred because of selection of ciprofloxacin-
resistant bacteria with regimens using more frequent dosing
(400 mg every 8 h or 600 mg every 12 h) or survival of small
numbers of ciprofloxacin-susceptible bacteria which per-
sisted and regrew with the regimen of 1,200 mg every 24 h
during prolonged periods of low concentrations of drug.
Studies with a methicillin-susceptible and a methicillin-
resistant strain of S. aureus demonstrated the rapid selection
of resistance to ciprofloxacin with the low dosage (200 mg
every 12 h) but not with the regimens of 400 or 600 mg every
12 h. Whether these higher-dosage regimens will result in a
reduced frequency of resistance when continued over a
longer period of exposure (as is the case with treatment of
human infection) clearly requires further study.
Although previous studies of fluoroquinolones against
gram-negative bacteria in in vitro (1, 6) and animal (8, 11)
models of infection and in humans (15) have examined the
relation between certain pharmacokinetic parameters and
outcomes, the results from these studies have at times
appeared to conflict with each other. However, the apparent
discrepancies between studies are often resolved when one
considers differences in study design, selection of improper
pharmacokinetic models, and use of a large bacterial inocu-
lum to measure the selection of bacterial resistance as an
endpoint (5). However, the weight of evidence indicates that
high peak concentrations relative to the MIC is the param-
eter associated with improved outcome, particularly when
selection for bacterial resistance leads to failure in clinical or
experimental infection (1, 4, 8). As with previous studies
with fluoroquinolones in this model, peak concentration/
MIC ratios of less than 10 were associated with selection of
drug-resistant populations of P. aeruginosa (1, 6). The
finding that shorter dosage intervals with a fixed dosage level
result in lower, sustained drug levels closer to the MIC is not
surprising, since these regimens most closely resemble lab-
oratory procedures to select for drug-resistant mutants in
vitro.
The data from the current study show the importance of
high-dose therapy resulting in a increased exposure of bac-
teria to ciprofloxacin during the early stages of therapy (e.g.,
the first 8 h) for the suppression of ciprofloxacin-resistant
bacteria. Our system is set up to test the worst-case exam-
ple, in which no host defenses are present, and results when
intact host defenses are present may be different. Further
studies evaluating the safety and efficacy of higher doses in
humans are required.
ACKNOWLEDGMENTS
The assistance of George Kroll with the HPLC assay of cipro-
floxacin samples and of Chris Neumann with helpful discussions is
acknowledged.
This work was supported in part by a grant from Miles Pharma-
ceuticals, West Haven, Conn.
REFERENCES
1. Blaser, J., B. B. Stone, M. C. Groner, and S. H. Zinner. 1987.
Comparative study with enoxacin and netilmicin in a pharma-
codynamic model to determine importance of ratio of antibiotic
ANTiMICROB. AGENTS CHEMOTHER.
 o
n
 June 5, 2018 by UNIV O
F RHO
DE ISLAND
http://aac.asm
.org/
D
ow
nloaded from
 
HIGH-DOSE CIPROFLOXACIN PHARMACODYNAMICS 1763
peak concentration to MIC for bacterial activity and emergence
of resistance. Antimicrob. Agents Chemother. 31:1054-1060.
2. Blaser, J., B. B. Stone, and S. H. Zinner. 1985. Two compart-
ment kinetic model with multiple artificial capillary units. J.
Antimicrob. Chemother. 15(Suppl. A):131-137.
3. Daikos, G. L., V. T. Lolans, and G. G. Jackson. 1988. Alter-
ations in outer membrane proteins ofPseudomonas aeruginosa
associated with selective resistance to quinolones. Antimicrob.
Agents Chemother. 32:785-787.
4. Dudley, M. N. 1991. Pharmacodynamics and pharmacokinetics
of antibiotics with special reference to the fluoroquinolones.
Am. J. Med. 91(Suppl. 6A):45S-SOS.
5. Dudley, M. N. 1992. Commentary on dual individualization with
antibiotics, p. 18-1-18-13. In W. E. Evans, J. J. Schentag, and
W. Jusko (ed.), Applied pharmacokinetics, 3rd ed. Applied
Therapeutics, Vancouver, Wash.
6. Dudley, M. N., J. Blaser, D. Gilbert, K. H. Mayer, and S. H.
Zinner. 1991. Combination therapy with ciprofloxacin plus
azlocillin against Pseudomonas aeruginosa: effect of simulta-
neous versus staggered administration in an in vitro model of
infection. J. Infect. Dis. 164:499-506.
7. Dudley, M. N., J. Ericson, and S. H. Zinner. 1987. Effect of dose
on serum pharmacokinetics of intravenous ciprofloxacin with
identification and characterization of extravascular compart-
ments using noncompartmental and compartmental pharmaco-
kinetic models. Antimicrob. Agents Chemother. 31:1782-1786.
8. Drusano, G. L., D. E. Johnson, M. Rosen, and H. C. Standiford.
1993. Pharmacodynamics of a fluoroquinolone antimicrobial
agent in a neutropenic rat model of Pseudomonas sepsis.
Antimicrob. Agents Chemother. 37:483-490.
9. Eron, L. J., L. Harvey, D. L. Hixon, and D. M. Poretz. 1985.
Ciprofloxacin therapy of infection caused by Pseudomonas
aeruginosa and other resistant bacteria. Antimicrob. Agents
Chemother. 27:308-310.
10. Kroll, G. J., A. J. Noe, and D. Beerman. 1986. Liquid chromato-
graphic analysis of ciprofloxacin and ciprofloxacin metabolites
in body fluids. J. Liq. Chromatogr. 9:2857-2919.
11. Leggett, J. E., S. Ebert, B. Fantin, and W. A. Craig. 1991.
Comparative dose-effect relations at several dosing intervals for
beta-lactam, aminoglycoside and quinolone antibiotics against
gram-negative bacilli in murine thigh infection and pneumonitis
models. Scand. J. Infect. Dis 74(Suppl.):179-184.
12. Masecar, B. L., R. A. Celesk, and N. J. Robillard. 1990. Analysis
of acquired ciprofloxacin resistance in a clinical strain of
Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 34:
281-286.
13. Meunier, F., S. H. Zinner, H. Gaya, T. Calandra, C. Viscoli, J.
Klastersky, M. Glauser, and the European Organization for
Research on Treatment of Cancer International Antimicrobial
Therapy Cooperative Group. 1991. Prospective randomized
evaluation of ciprofloxacin versus piperacillin plus amikacin for
empiric antibiotic therapy of febrile granulocytopenic cancer
patients with lymphomas and solid tumors. Antimicrob. Agents
Chemother. 35:873-878.
14. Michea-Hamzehpour, M., R. Auckenthaler, P. Regemey, and
J. C. Pechere. 1987. Resistance occurring after fluoroquinolone
therapy of experimental Pseudomonas aeruginosa peritonitis.
Antimicrob. Agents Chemother. 31:1803-1808.
15. National Committee for Clinical Laboratory Standards. 1983.
Standard methods for dilution antimicrobial susceptibility tests
for bacteria which grow aerobically; tentative standards. Doc-
ument M7-T. National Committee for Clinical Laboratory Stan-
dards, Villanova, Pa.
16. Ogle, J. W., L. B. Reller, and M. L. Vasil. 1988. Development of
resistance in Pseudomonas aeruginosa to imipenem, norfloxa-
cin, and ciprofloxacin during therapy: proof provided by typing
with a DNA probe. J. Infect. Dis. 157:743-748.
17. Peloquin, C. A., J. J. Cumbo, D. E. Nix, M. F. Sands, and J. J.
Schentag. 1989. Evaluation of intravenous ciprofloxacin in pa-
tients with nosocomial lower respiratory tract infections. Im-
pact of plasma concentrations, organisms, minimum inhibitory
concentration, and clinical condition on bacterial eradication.
Arch. Intern. Med. 149:2269-2273.
18. Roberts, C. M., J. Batten, and M. E. Hodson. 1985. Ciproflox-
acin-resistant Pseudomonas. Lancet i:l442.
19. Robillard, N. J. 1990. Broad-host-range gyrase A gene probe.
Antimicrob. Agents Chemother. 34:1889-1894.
20. Robillard, N. J., and A. L. Scarpa. 1988. Genetic and physio-
logical characterization of ciprofloxacin resistance in Pseudo-
monas aeruginosa PAO. Antimicrob. Agents Chemother. 32:
535-539.
21. Scully, B. E., H. C. Neu, M. F. Parry, and W. Mandell. 1986.
Oral ciprofloxacin therapy of infections due to Pseudomonas
aeruginosa. Lancet i:819-822.
22. Wolfson, J. S., and D. C. Hooper. 1989. Bacterial resistance to
quinolones: mechanisms and clinical importance. Rev. Infect.
Dis. ll:S960-S968.
23. Wolfson, J. S., D. C. Hooper, D. J. Shih, G. L. McHugh, and
M. N. Schwartz. 1989. Isolation and characterization of an
Escherichia coli strain exhibiting partial tolerance to quino-
lones. Antimicrob. Agents Chemother. 33:705-709.
VOL. 37, 1993
 o
n
 June 5, 2018 by UNIV O
F RHO
DE ISLAND
http://aac.asm
.org/
D
ow
nloaded from
 
